Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Verheyen, N; Grübler, MR; Meinitzer, A; Trummer, C; Schwetz, V; Amrein, K; Dimai, HP; März, W; Catena, C; von Lewinski, D; Voelkl, J; Alesutan, I; Fahrleitner-Pammer, A; Brussee, H; Pilz, S; Tomaschitz, A.
Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism - The randomized, placebo-controlled EPATH trial.
Bone. 2017; 105(5):212-217 Doi: 10.1016/j.bone.2017.08.030
Web of Science PubMed FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Verheyen Nicolas Dominik
Co-Autor*innen der Med Uni Graz
Amrein Karin
Brussee Helmut
Dimai Hans Peter
Fahrleitner-Pammer Astrid
Grübler Martin
März Winfried
Meinitzer Andreas
Pilz Stefan
Theiler-Schwetz Verena
Tomaschitz Andreas
Trummer Christian
von Lewinski Dirk

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Mineralocorticoid receptor (MR) antagonism may affect bone turnover via direct and indirect pathways involving parathyroid hormone, but randomized controlled trials are lacking. In a pre-specified analysis of the "Eplerenone in primary hyperparathyroidism" placebo-controlled, randomized trial (ISRCTN 33941607), effects of eight weeks MR-blockade with eplerenone on bone turnover markers in 97 patients with primary hyperparathyroidism were tested. Mean age was 67.5±9.5years, and 76 (78.4%) were females. In analysis of covariance with adjustment for baseline values, eplerenone had no significant effect on isoform 5b of the tartrate-resistant acid phosphatase (TRAP), beta-crosslaps, N-terminal propeptide of procollagen type 1 (P1NP), osteocalcin and bone-specific alkaline phosphatase. There was no significant cross-sectional correlation between plasma aldosterone concentration or the aldosterone-to-renin ratio and markers of bone turnover in multivariate linear regression models at baseline. These data provide first evidence from a randomized and placebo-controlled trial that short-term MR antagonism may not affect bone turnover, at least in patients with primary hyperparathyroidism. Copyright © 2017 Elsevier Inc. All rights reserved.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Biomarkers - metabolism
Bone Remodeling - drug effects
Cohort Studies -
Female -
Follow-Up Studies -
Humans -
Hyperparathyroidism, Primary - drug therapy
Hyperparathyroidism, Primary - metabolism
Male -
Placebos -
Renin-Angiotensin System -
Spironolactone - analogs & derivatives
Spironolactone - pharmacology
Spironolactone - therapeutic use
Treatment Outcome -

Find related publications in this database (Keywords)
Bone turnover
Mineralocorticoid receptor
Primary hyperparathyroidism
Randomized controlled trial
© Med Uni Graz Impressum